Nintedanib and Its Combination with Immunosuppressives in Connective Tissue Disease-related Interstitial Lung Diseases

Overview

Journal Ir J Med Sci

Specialty General Medicine

Date 2024 Dec 5

PMID 39636517

Authors

Emre Tekgoz

Seda Yurumez Colak

Ezgi Cimen Gunes

Nesrin Ocal

Muhammet Cinar

Sedat Yilmaz

Affiliations

Soon will be listed here.

Abstract

Background: Nintedanib reduces the decline of pulmonary function in patients with advancing lung fibrosis.

Aim: To assess the characteristics of the patients with connective tissue diseases (CTDs) related to interstitial lung disease (ILD) under nintedanib treatment.

Methods: The CTD-related ILD patients under nintedanib treatment who were followed up between 2020 and 2023 were included in the study. The clinical data of the patients before and after nintedanib were evaluated retrospectively.

Results: There were 36 patients (19 female) with a mean age of 65.2 ± 8.5 years who were treated with nintedanib. The median duration for nintedanib treatment was 19 months. The most common CTD was Sjogren's syndrome (36.1%), followed by systemic sclerosis (27.8%), rheumatoid arthritis (25%), undifferentiated CTD (8.3%), and inflammatory myositis (2.8%). Fifteen (41.7%) patients had impaired pulmonary function tests (FVC < 70 ml and/or DLco < 80 ml), and 23 (63.9%) patients had ≥ 20% involvement of parenchyma in high-resolution computed tomography (HRCT) before nintedanib. According to HRCT findings, 25 (69.4%) patients had the usual interstitial pneumonia pattern. All patients had 300 mg/day of nintedanib and received at least one immunosuppressive treatment during the study period. The mean %predicted value of FVC was 82.8 ± 17.6, and DLco was 65.3 ± 19.2 before nintedanib treatment. Following the 6-month follow-up, FVC showed an increase to 92.3 ± 15.8 (with an R correlation coefficient of 0.54, p = 0.025), and 22 (61.1%) patients exhibited either stabilization or regression of findings on HRCT.

Conclusions: Nintedanib emerges as a promising therapeutic agent compatible with immunosuppressives for treating progressive lung fibrosis in patients with CTD-related ILD.

References

Rajan S, Cottin V, Dhar R, Danoff S, Flaherty K, Brown K . Progressive pulmonary fibrosis: an expert group consensus statement. Eur Respir J. 2022; 61(3). PMC: 10060665. DOI: 10.1183/13993003.03187-2021. View

Spagnolo P, Distler O, Ryerson C, Tzouvelekis A, Lee J, Bonella F . Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). Ann Rheum Dis. 2020; 80(2):143-150. PMC: 7815631. DOI: 10.1136/annrheumdis-2020-217230. View

Juge P, Borie R, Kannengiesser C, Gazal S, Revy P, Wemeau-Stervinou L . Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis. Eur Respir J. 2017; 49(5). DOI: 10.1183/13993003.02314-2016. View

Liu G, Budinger G, Dematte J . Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. BMJ. 2023; 377:e066354. DOI: 10.1136/bmj-2021-066354. View

McCormack P . Nintedanib: first global approval. Drugs. 2014; 75(1):129-39. DOI: 10.1007/s40265-014-0335-0. View

Richeldi L, du Bois R, Raghu G, Azuma A, Brown K, Costabel U . Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22):2071-82. DOI: 10.1056/NEJMoa1402584. View

Flaherty K, Wells A, Cottin V, Devaraj A, Walsh S, Inoue Y . Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019; 381(18):1718-1727. DOI: 10.1056/NEJMoa1908681. View

Distler O, Highland K, Gahlemann M, Azuma A, Fischer A, Mayes M . Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med. 2019; 380(26):2518-2528. DOI: 10.1056/NEJMoa1903076. View

Raghu G, Remy-Jardin M, Richeldi L, Thomson C, Inoue Y, Johkoh T . Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022; 205(9):e18-e47. PMC: 9851481. DOI: 10.1164/rccm.202202-0399ST. View

10.

Bruni T, Varone F . The adoption of nintedanib in systemic sclerosis: the SENSCIS study. Breathe (Sheff). 2020; 16(2):200005. PMC: 7341613. DOI: 10.1183/20734735.0005-2020. View

11.

Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A . Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017; 76(11):1897-1905. DOI: 10.1136/annrheumdis-2017-211448. View

12.

Ushio Y, Wakiya R, Kameda T, Nakashima S, Shimada H, Miyagi T . Nintedanib combined with immunosuppressive agents improves forced vital capacity in connective tissue disease-associated PF-ILD: a single-center study. BMC Rheumatol. 2024; 8(1):27. PMC: 11184786. DOI: 10.1186/s41927-024-00400-y. View

13.

Knarborg M, Hyldgaard C, Bendstrup E, Davidsen J, Lokke A, Shaker S . Incidence, prevalence and regional distribution of systemic sclerosis and related interstitial lung Disease: A nationwide retrospective cohort study. Chron Respir Dis. 2022; 19:14799731221125559. PMC: 9500307. DOI: 10.1177/14799731221125559. View

14.

Baresic M, Novak S, Perkovic D, Karanovic B, Miric F, Radic M . Real world experience with nintedanib in connective tissue disease-related interstitial lung disease: a retrospective cohort study. Clin Rheumatol. 2023; 42(10):2897-2903. DOI: 10.1007/s10067-023-06689-3. View

15.

Tashkin D, Elashoff R, Clements P, Goldin J, Roth M, Furst D . Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006; 354(25):2655-66. DOI: 10.1056/NEJMoa055120. View

16.

Tashkin D, Roth M, Clements P, Furst D, Khanna D, Kleerup E . Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016; 4(9):708-719. PMC: 5014629. DOI: 10.1016/S2213-2600(16)30152-7. View

17.

Hoyles R, Ellis R, Wellsbury J, Lees B, Newlands P, Goh N . A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006; 54(12):3962-70. DOI: 10.1002/art.22204. View

18.

Xu J, Xiao L, Zhu J, Qin Q, Fang Y, Zhang J . Methotrexate use reduces mortality risk in rheumatoid arthritis: A systematic review and meta-analysis of cohort studies. Semin Arthritis Rheum. 2022; 55:152031. DOI: 10.1016/j.semarthrit.2022.152031. View

19.

Mena-Vazquez N, Rojas-Gimenez M, Romero-Barco C, Manrique-Arija S, Francisco E, Aguilar-Hurtado M . Predictors of Progression and Mortality in Patients with Prevalent Rheumatoid Arthritis and Interstitial Lung Disease: A Prospective Cohort Study. J Clin Med. 2021; 10(4). PMC: 7924396. DOI: 10.3390/jcm10040874. View

20.

Mena-Vazquez N, Godoy-Navarrete F, Manrique-Arija S, Aguilar-Hurtado M, Romero-Barco C, Urena-Garnica I . Non-anti-TNF biologic agents are associated with slower worsening of interstitial lung disease secondary to rheumatoid arthritis. Clin Rheumatol. 2020; 40(1):133-142. DOI: 10.1007/s10067-020-05227-9. View